Premium
Progressive Supranuclear Palsy and Statin Use
Author(s) -
Bayram Ece,
Marras Connie,
Standaert David G.,
Kluger Benzi M.,
Bordelon Yvette M.,
Shprecher David R.,
Litvan Irene
Publication year - 2020
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.28038
Subject(s) - pravastatin , progressive supranuclear palsy , medicine , rating scale , rosuvastatin , atorvastatin , clinical dementia rating , physical therapy , psychology , dementia , disease , cholesterol , developmental psychology
Statins were proposed to be neuroprotective; however, the effects are unknown in progressive supranuclear palsy (PSP), a pure tauopathy. Methods Data of 284 PSP cases and 284 age‐matched, sex‐matched, and race‐matched controls were obtained from the environmental and genetic PSP (ENGENE‐PSP) study. Cases were evaluated with the PSP Rating Scale, Unified Parkinson's Disease Rating Scale, Mattis Dementia Rating Scale, and Neuropsychiatric Inventory. Statin associations with PSP risk, onset age, and disease features were analyzed. Results Univariate models showed lower PSP risk for type 1 statin users (simvastatin, lovastatin, pravastatin). After adjusting for confounding variables, statin use and lower PSP risk association remained only at a trend level. For PSP cases, type 1 statins were associated with 1‐year older onset age; type 2 statins (atorvastatin, rosuvastatin) were associated with the lower PSP Rating Scale and Unified Parkinson's Disease Rating Scale. Conclusion Statins may have inverse associations with PSP risk and motor impairment. Randomized prospective studies are required to confirm this effect. © 2020 International Parkinson and Movement Disorder Society